During the COVID-19 pandemic, pharmaceutical companies raced to develop a vaccine, with Moderna quickly rising to prominence. In 2022, Moderna decided to enforce its COVID-19 vaccine patents to maintain its competitive edge, despite earlier claims that it wouldn’t.
Moderna’s main competitor, Pfizer, denies any infringement, asserting its own R&D techniques. As of December 2022, the patent dispute continues in US courts and could become as prolonged and costly as the Apple vs. Samsung case.
This litigation may also set new precedents for protecting life-saving patents during global crises.
#ExyIP #Patent #Covid-19 #pandemic #Moderna #Pfizer